Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (31-40 of 284) with videos related to

Pageof 29
Sort By:
Cancer Research|September 6, 2005
Epidermal growth factor receptor mutations in patients with non-small cell lung cancerBruce E Johnson, Pasi A Jänne
Family Medicine|January 4, 2008
Family medicine practice in rural any-countryCynda Ann Johnson, Bruce E Johnson
Lancet (London, England)|October 18, 2005
Small-cell lung cancerDavid M Jackman, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancerBruce E Johnson, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Farnesyl transferase inhibitors for patients with lung cancerBruce E Johnson, John V Heymach
Annals of Internal Medicine|February 17, 2010
ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal womenBruce E Johnson, Cynda A Johnson
Annals of Internal Medicine|February 28, 2017
Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspectiveBruce E Johnson, Elvis R Pagan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancerBruce E Johnson, David Jackman, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancerBoris Freidlin, Oscar S Breathnach, Bruce E Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial settingDavid A Eberhard, Giuseppe Giaccone, Bruce E Johnson, et al.
Pageof 29

Showing results (31-40 of 284) with videos related to

Sort By:
Pageof 29
Cancer Research|September 6, 2005
Epidermal growth factor receptor mutations in patients with non-small cell lung cancerBruce E Johnson, Pasi A Jänne
Family Medicine|January 4, 2008
Family medicine practice in rural any-countryCynda Ann Johnson, Bruce E Johnson
Lancet (London, England)|October 18, 2005
Small-cell lung cancerDavid M Jackman, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancerBruce E Johnson, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Farnesyl transferase inhibitors for patients with lung cancerBruce E Johnson, John V Heymach
Annals of Internal Medicine|February 17, 2010
ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal womenBruce E Johnson, Cynda A Johnson
Annals of Internal Medicine|February 28, 2017
Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspectiveBruce E Johnson, Elvis R Pagan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancerBruce E Johnson, David Jackman, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancerBoris Freidlin, Oscar S Breathnach, Bruce E Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial settingDavid A Eberhard, Giuseppe Giaccone, Bruce E Johnson, et al.
Pageof 29